Zenas BioPharma, Inc. (ZBIO)
NASDAQ: ZBIO · Real-Time Price · USD
22.30
-1.07 (-4.58%)
At close: Mar 20, 2026, 4:00 PM EDT
22.63
+0.33 (1.48%)
After-hours: Mar 20, 2026, 5:07 PM EDT
Zenas BioPharma Stock Forecast
Stock Price Forecast
The 7 analysts that cover Zenas BioPharma stock have a consensus rating of "Strong Buy" and an average price target of $42.14, which forecasts a 88.97% increase in the stock price over the next year. The lowest target is $21 and the highest is $55.
Price Target: $42.14 (+88.97%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zenas BioPharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 3 | 5 | 5 | 4 | 3 | 3 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $43 → $41 | Strong Buy | Maintains | $43 → $41 | +83.86% | Mar 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $45 → $55 | Strong Buy | Maintains | $45 → $55 | +146.64% | Mar 17, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $19 → $21 | Hold | Maintains | $19 → $21 | -5.83% | Mar 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +97.31% | Mar 17, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $44 | Strong Buy | Reiterates | $44 | +97.31% | Feb 10, 2026 |
Financial Forecast
Revenue This Year
n/a
from 10.00M
Revenue Next Year
52.71M
EPS This Year
-4.65
from -8.44
EPS Next Year
-4.44
from -4.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | n/a | 95.1M | |||
| Avg | n/a | 52.7M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -3.64 | -2.99 | |||
| Avg | -4.65 | -4.44 | |||
| Low | -5.47 | -5.28 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.